The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias

På svenska

Author

Summary, in English

Appearance of dyskinesia is a common problem of long-term Levodopa (L-DOPA) treatment in Parkinson's disease (PD) patients and represents a major limitation for the pharmacological management of the motor symptoms in the advanced stages of disease. An increasing body of evidence points to dopamine released as a false neurotransmitter from the striatal serotonin terminals as the main pre-synaptic determinant of L-DOPA-induced dyskinesia. Here we review the animal experimental and human clinical data in support of this view, which point to the serotonin system as a promising target for anti-dyskinetic therapy in PD patients under L-DOPA medication.

Publishing year

2008

Language

English

Pages

465-478

Publication/Series

Progress in Brain Research

Volume

172

Document type

Journal article

Publisher

Elsevier

Topic

  • Neurosciences

Keywords

  • Animals
  • Clinical Trials as Topic
  • Dopamine
  • Dyskinesia, Drug-Induced
  • Humans
  • Levodopa
  • Parkinson Disease
  • Parkinsonian Disorders
  • Presynaptic Terminals
  • Protein Isoforms
  • Receptors, Dopamine
  • Receptors, Serotonin
  • Serotonin
  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Review

Status

Published

Research group

  • Neurobiology
  • Brain Repair and Imaging in Neural Systems (BRAINS)

ISBN/ISSN/Other

  • ISSN: 1875-7855